%0 Journal Article
%T Intramuscular Anti-D treatment for immune thrombocytopenia: A single centre experience.
%A Lakhwani S
%A López-Las Heras A
%A Rodríguez-García P
%A Iraheta S
%A Martín-Santos T
%A Rodríguez-Salazar MJ
%A Machado P
%A Hernández MT
%J Br J Haematol
%V 200
%N 3
%D 02 2023
%M 36198407
%F 8.615
%R 10.1111/bjh.18484
%X Intravenous Anti-Rhesus-D immunoglobulin (Anti-D) is a first-line treatment option for immune thrombocytopenia in non-splenectomised and RhD-positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti-D treatment in 74 adult patients between 1990 and 2018. We found that 73% of patients showed a response; almost all of them had complete responses (68.9%), and 26% achieved complete responses sustained at least 6 months after treatment discontinuation. [Correction added on 02 December 2022, after first online publication: In the preceding sentence, '(68.89%)' has been corrected to '(68.9%)' in this version.] No significant side effects were observed with no cases of acute haemolysis or anaemia reported. We conclude from this study that IM Anti-D is an effective and safe treatment for immune thrombocytopenia.